StockMarketWire.com - IXICO has signed a new contract with another leading biopharmaceutical company to support the use of wrist worn activity sensors ('wearable biosensors') in a late stage trial for a psychiatric disorder. IXICO said the contract had a value around £0.75m over a two year term, commencing this month.

IXICO said it would utilise its biosensor capabilities, combined with its artificial intelligence data analytics algorithms, to measure sleep, day time napping, overall daily activity levels and patterns using data collected from c.200 people at multiple time points.

It said the study would allow the exploratory digital measures of patient quality of life to be evaluated alongside standard clinical measures.

This is IXICO's second commercial agreement involving wearable biosensors and follows on from a contract announced on 4 Oct to measure sleep disturbance from biosensor data collected from people with a neurological disorder.

Chief executive Giulio Cerroni said: 'We are delighted to announce this first contract with a new biopharma customer, providing our wearable biosensor capabilities and technology to support this late phase clinical trial.

'This study is focused on monitoring the treatment of patients with a serious psychiatric disorder, further supporting our view that wearable biosensors have broad utility in clinical research in many therapeutic areas.

'These two contracts represent an excellent opportunity for IXICO to provide new, innovative digital technologies as part of our commercially led growth strategy.'


At 8:20am: [LON:IXI] IXICO plc share price was +1.5p at 35.5p



Story provided by StockMarketWire.com